Your browser doesn't support javascript.
loading
Defining milestones for the study of remyelination using the cuprizone mouse model: How early is early?
Palavra, Filipe; Viana, Sofia D; Henriques, Sara; Dinis, João; Martins, João; Madeira, Maria H; Santiago, Raquel; Petrella, Lorena; Sereno, José; Castelo-Branco, Miguel; Pereira, Frederico C; Almeida, Luís; Ambrósio, António F; Reis, Flávio.
Afiliación
  • Palavra F; Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Celas, Coimbra 3000-548, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Port
  • Viana SD; Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Celas, Coimbra 3000-548, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Port
  • Henriques S; Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Celas, Coimbra 3000-548, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Port
  • Dinis J; Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Celas, Coimbra 3000-548, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Port
  • Martins J; Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Celas, Coimbra 3000-548, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Port
  • Madeira MH; Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Celas, Coimbra 3000-548, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Port
  • Santiago R; Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Celas, Coimbra 3000-548, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Port
  • Petrella L; Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), University of Coimbra, Coimbra, Portugal; Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal.
  • Sereno J; Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), University of Coimbra, Coimbra, Portugal; Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal.
  • Castelo-Branco M; Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), University of Coimbra, Coimbra, Portugal; Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal.
  • Pereira FC; Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Celas, Coimbra 3000-548, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Port
  • Almeida L; Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Celas, Coimbra 3000-548, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Port
  • Ambrósio AF; Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Celas, Coimbra 3000-548, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Port
  • Reis F; Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Celas, Coimbra 3000-548, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Port
Mult Scler Relat Disord ; 63: 103886, 2022 Jul.
Article en En | MEDLINE | ID: mdl-35597080
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades Desmielinizantes / Remielinización / Esclerosis Múltiple Límite: Animals / Humans / Male Idioma: En Revista: Mult Scler Relat Disord Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades Desmielinizantes / Remielinización / Esclerosis Múltiple Límite: Animals / Humans / Male Idioma: En Revista: Mult Scler Relat Disord Año: 2022 Tipo del documento: Article